Higher NT-proBNP levels were significantly associated with higher incidences of stroke/systemic embolism, all-cause death, and HF hospitalization over a median 5.0 years (log rank P<0.001).
Cohort (n=1,159)
Do natriuretic peptide levels predict adverse outcomes in patients with atrial fibrillation without heart failure?
NT-proBNP levels are an independent prognostic marker for stroke, death, and heart failure hospitalization in patients with atrial fibrillation who do not have baseline heart failure.
p-value: p=<0.001
OBJECTIVES: Natriuretic peptides are an important prognostic marker in patients with heart failure (HF). However, little is known regarding their prognostic significance in patients with atrial fibrillation (AF) without HF and natriuretic peptides levels are underused in these patients in daily practice. METHODS: The Fushimi AF Registry is a community-based prospective survey of patients with AF in Fushimi-ku, Kyoto, Japan. We investigated patients with AF without HF (defined as prior HF hospitalisation, New York Heart Association functional class≥2 or left ventricular ejection fraction<40%) using the data of B-type natriuretic peptide (BNP, n=388) or N-terminal pro-B-type natriuretic peptide (NT-proBNP, n=771) at enrolment. BNPs were converted to NT-proBNP using a conversion formula. We divided the patients according to quartiles of NT-proBNP levels and compared the backgrounds and outcomes. RESULTS: -VASc scores and had more OAC prescription (all p<0.001). Kaplan-Meier curves demonstrated that NT-proBNP levels were significantly associated with higher incidences of stroke/systemic embolism, all-cause death and HF hospitalisation during a median follow-up period of 5.0 years (log rank, all p<0.001). Multivariable Cox regression analyses revealed that NT-proBNP levels were an independent predictor of adverse outcomes even after adjustment by various confounders. CONCLUSION: NT-proBNP levels are a significant prognostic marker for adverse outcomes in patients with AF without HF and may have clinical value. TRIAL REGISTRATION NUMBER: UMIN000005834.
Hamatani et al. (2020) conducted a cohort in Atrial fibrillation without heart failure (n=1,159). NT-proBNP levels vs. Lower quartiles of NT-proBNP levels was evaluated on Stroke/systemic embolism, all-cause death and HF hospitalisation (p=<0.001). Higher NT-proBNP levels were significantly associated with higher incidences of stroke/systemic embolism, all-cause death, and HF hospitalization over a median 5.0 years (log rank P<0.001).